A C Wolff

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
    Antonio C Wolff
    Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    J Clin Oncol 31:195-202. 2013
  2. ncbi request reprint Systemic therapy
    A C Wolff
    The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Curr Opin Oncol 11:468-74. 1999
  3. doi request reprint Research issues affecting preoperative systemic therapy for operable breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 189, Baltimore, MD 21231 1000, USA
    J Clin Oncol 26:806-13. 2008
  4. ncbi request reprint A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 9:5922-8. 2003
  5. ncbi request reprint Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21230 1000, USA
    Clin Cancer Res 9:3589-97. 2003
  6. ncbi request reprint Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Breast Cancer 6:334-9. 2005
  7. ncbi request reprint Systemic therapy
    Antonio C Wolff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Curr Opin Oncol 14:600-8. 2002
  8. pmc Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 121:111-20. 2010
  9. ncbi request reprint Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Oncologist 7:239-45. 2002
  10. ncbi request reprint Adjuvant systemic management of early stage carcinoma of the breast
    A C Wolff
    Division of Medical Oncology, The Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
    Surg Oncol 8:93-101. 1999

Detail Information

Publications64

  1. pmc Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
    Antonio C Wolff
    Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    J Clin Oncol 31:195-202. 2013
    ..Here, we report clinical outcomes of combining the mammalian target of rapamycin (mTOR) inhibitor temsirolimus with letrozole in AI-naive patients...
  2. ncbi request reprint Systemic therapy
    A C Wolff
    The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Curr Opin Oncol 11:468-74. 1999
    ..Early results of high-dose chemotherapy have been released, and the role of taxanes in early and advanced disease continues to expand. This article reviews these and other recent advances...
  3. doi request reprint Research issues affecting preoperative systemic therapy for operable breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 189, Baltimore, MD 21231 1000, USA
    J Clin Oncol 26:806-13. 2008
    ..PST requires an experienced and cohesive multidisciplinary team for it to fulfill its potential in both research and clinical care...
  4. ncbi request reprint A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 9:5922-8. 2003
    ..This study evaluated the activity of the first-generation analog DENSpm in women with metastatic breast cancer...
  5. ncbi request reprint Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21230 1000, USA
    Clin Cancer Res 9:3589-97. 2003
    ..This Phase I trial examined its toxicity and pharmacokinetics (PKs)...
  6. ncbi request reprint Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Breast Cancer 6:334-9. 2005
    ..The purpose of this multicenter phase II trial was to evaluate the clinical activity of topotecan as first-line chemotherapy in patients with metastatic breast cancer and previous exposure to adjuvant doxorubicin...
  7. ncbi request reprint Systemic therapy
    Antonio C Wolff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Curr Opin Oncol 14:600-8. 2002
    ..These and other important developments since 2001 are examined in this review...
  8. pmc Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 121:111-20. 2010
    ..In conclusion, concurrent administration of trastuzumab with PLD-docetaxel was not associated with higher risk of cardiac toxicity compared with PLD-docetaxel alone, but led to excessive hand-foot syndrome...
  9. ncbi request reprint Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Oncologist 7:239-45. 2002
    ..PST is increasingly being used in otherwise operable stage I and II patients aiming at greater rates of breast conservation and earlier efficacy assessment. This article reviews many of these issues and ongoing research questions...
  10. ncbi request reprint Adjuvant systemic management of early stage carcinoma of the breast
    A C Wolff
    Division of Medical Oncology, The Johns Hopkins Oncology Center, Baltimore, MD 21287, USA
    Surg Oncol 8:93-101. 1999
    ..This specific topic is discussed elsewhere in this issue by Singletary...
  11. ncbi request reprint Systemic therapy
    A C Wolff
    The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Curr Opin Oncol 12:532-40. 2000
    ..Data continue to evolve on the role and optimal schedules of taxanes in early-stage and advanced breast cancer. These and other important recent findings are discussed in this review article...
  12. ncbi request reprint Systemic therapy
    A C Wolff
    The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Curr Opin Oncol 13:436-49. 2001
    ..Discussions on the long-term effects of adjuvant therapy have taken center stage also. These and other important ongoing developments since 2000 are examined in this review article...
  13. ncbi request reprint Use of SERMs for the adjuvant therapy of early-stage breast cancer
    A C Wolff
    The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Ann N Y Acad Sci 949:80-8. 2001
    ..At present, SERMs are recognized as the first targeted and relatively nontoxic medical therapy for women with high-risk or steroid hormone receptor-positive breast cancer...
  14. ncbi request reprint Primary systemic therapy in operable breast cancer
    A C Wolff
    Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
    J Clin Oncol 18:1558-69. 2000
    ..This article examines the rationale for and preclinical and clinical data of PST in operable breast cancer and the potential role of intermediate biomarkers as predictive and/or prognostic factors for response and survival...
  15. doi request reprint Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer
    Saranya Chumsri
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21231, USA
    Clin Breast Cancer 10:40-5. 2010
    ..We evaluated pathologic complete response (pCR) rate and cardiac safety of preoperative doxorubicin and cyclophosphamide followed by a taxane with or without trastuzumab...
  16. pmc Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
    Wells A Messersmith
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, CRB 1M88, 1650 Orleans Street, Baltimore, MD 21231, USA
    Eur J Cancer 43:78-86. 2007
    ..A long half-life and accumulation of BPU and active metabolites were observed, recommending against a continuous administration. Weekly oral BPU therapy should be further tested using an interrupted schedule...
  17. ncbi request reprint Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer
    Susanne Briest
    University of Leipzig, Department of Gynecology and Obstetrics, Leipzig, Germany
    Expert Rev Anticancer Ther 7:1243-53. 2007
    ..This review discusses basic principles regarding endocrine therapy, the need for accurate estrogen receptor testing and the role of menopause in therapy selection...
  18. pmc Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis
    Kelly B Stein
    Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Dig Dis Sci 55:1839-51. 2010
    ....
  19. ncbi request reprint Therapeutic options in the management of metastatic breast cancer
    Michaela J Higgins
    Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland 21231 1000, USA
    Oncology (Williston Park) 22:614-23; discussion 623, 627-9. 2008
    ..Other novel agents are adding to the wide choices of standard chemotherapies already available. This review offers an approach to the selection of individualized and rational therapies for patients with metastatic breast cancer...
  20. doi request reprint Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer
    Richard C Zellars
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, 401 N Broadway, Suite 1440, Baltimore, MD 21231, USA
    J Clin Oncol 27:2816-22. 2009
    ..We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC)...
  21. pmc Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
    ..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
  22. pmc Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis
    Kimberly S Peairs
    Division of General Internal Medicine, Johns Hopkins University School of Medicine, 10753 Falls Rd, Suite 325, Lutherville, MD 21093, USA
    J Clin Oncol 29:40-6. 2011
    ..The goal of this study was to perform a systematic review and meta-analysis to examine the effect of pre-existing diabetes on breast cancer-related outcomes...
  23. pmc Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers
    Melinda Kantsiper
    Johns Hopkins University School of Medicine, 5200 Eastern Ave, MFL West, Baltimore, MD 21224 2780, USA
    J Gen Intern Med 24:S459-66. 2009
    ..Limited research exists regarding views of patients, oncology specialists, and primary care providers (PCPs) concerning breast cancer survivorship care...
  24. ncbi request reprint Comparative pharmacokinetics of weekly and every-three-weeks docetaxel
    Sharyn D Baker
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 10:1976-83. 2004
    ..The comparative pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) administration schedules were evaluated...
  25. ncbi request reprint Local failure and prognostic factors in ductal carcinoma in situ: concentration on recent publications
    Richard Zellars
    Division of Radiation Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 2410, USA
    Curr Opin Obstet Gynecol 15:9-12. 2003
    ..The purpose of this review is to assess the value of commonly accepted potential prognostic factors in patients with ductal carcinoma in situ...
  26. ncbi request reprint Liposomal anthracyclines and new treatment approaches for breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, Maryland 21231 1000, USA
    Oncologist 8:25-30. 2003
    ....
  27. pmc Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study
    Claire F Snyder
    Johns Hopkins School of Medicine, Baltimore, MD, USA
    J Gen Intern Med 24:469-74. 2009
    ..Deficiencies in care for cancer survivors may result from unclear roles for primary care providers (PCPs) and oncology specialists in follow-up...
  28. ncbi request reprint The role of ovarian ablation in the adjuvant therapy of breast cancer
    Sing Huang Tan
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1 189, Baltimore, MD 21231, USA
    Curr Oncol Rep 10:27-37. 2008
    ....
  29. ncbi request reprint Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
    M A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Eur J Cancer 40:1170-8. 2004
    ..Overall, these findings suggest that incorporation of variables in addition to BSA should be considered in routine dosing strategies for doxorubicin and docetaxel...
  30. pmc Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis
    Bethany B Barone
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    JAMA 300:2754-64. 2008
    ..Diabetes mellitus appears to be a risk factor for some cancers, but the effect of preexisting diabetes on all-cause mortality in newly diagnosed cancer patients is less clear...
  31. ncbi request reprint Systematic review: gene expression profiling assays in early-stage breast cancer
    Luigi Marchionni
    Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA
    Ann Intern Med 148:358-69. 2008
    ..Three gene expression-based prognostic breast cancer tests have been licensed for use...
  32. doi request reprint Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002
    Claire F Snyder
    Johns Hopkins University, 624 N Broadway, Rm 657, Baltimore, MD 21205, USA
    J Clin Oncol 27:1054-61. 2009
    ..To examine how care for breast cancer survivors compares with controls...
  33. doi request reprint Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 19:837-45. 2010
    ..We explored using needs assessments to identify HRQOL scores associated with patient-reported unmet needs...
  34. pmc Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis
    Bethany B Barone
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA
    Diabetes Care 33:931-9. 2010
    ..Study population and design, results, and quality components were abstracted with standard protocols by one reviewer and checked for accuracy by additional reviewers...
  35. doi request reprint Concordance of cancer patients' function, symptoms, and supportive care needs
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 18:991-8. 2009
    ..Although patients' function, symptoms, and supportive care needs are obviously related, a better understanding of these relationships could improve patient management...
  36. ncbi request reprint A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Biomed Chromatogr 18:282-7. 2004
    ..The lower limit of quantitation of 0.01 microg/mL allows for successful measurement of plasma concentrations in patients...
  37. pmc Symptoms, supportive care needs, and function in cancer patients: how are they related?
    Claire F Snyder
    Johns Hopkins School of Medicine, Baltimore, MD, USA
    Qual Life Res 17:665-77. 2008
    ..To explore the associations among symptoms, supportive care needs, and function...
  38. ncbi request reprint Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice
    Claire F Snyder
    Division of General Internal Medicine, Johns Hopkins School of Medicine, 624 N Broadway, 6th Floor, Baltimore, MD 21205, USA
    Support Care Cancer 15:1075-85. 2007
    ..We investigated the item content from two health-related quality-of-life (HRQOL) questionnaires and two needs assessments for this purpose...
  39. ncbi request reprint Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies
    Michelle A Rudek
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 1M86, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 828:41-54. 2005
    ..1-20, 0.1-20, 0.5-100, 10-2000, 1-200, and 3-600 ng/mL for BPU, mmBPU, aminoBPU, G280, G308, and G322 in urine, respectively. The method has been successfully applied to study the pharmacokinetics of BPU...
  40. ncbi request reprint Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications
    Michael A Jacobs
    The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Technol Cancer Res Treat 3:543-50. 2004
    ..A combination of MR, MRSI, and 23Na sodium MR parameters may be examined in a single MR imaging examination, potentially resulting in improved specificity for radiologic evaluation of malignancy...
  41. ncbi request reprint In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
    Michelle A Rudek
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 11:8503-11. 2005
    ....
  42. ncbi request reprint Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI
    Ronald Ouwerkerk
    Division of MR Research, Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21287 0845, USA
    Breast Cancer Res Treat 106:151-60. 2007
    ....
  43. ncbi request reprint Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer
    Mary Cianfrocca
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncology (Williston Park) 21:63-9; discussion 69, 72, 75 passim. 2007
    ..Issues regarding the optimal approach to endocrine therapy in both pre- and postmenopausal women are examined in this review...
  44. ncbi request reprint A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, Indiana, USA
    Clin Cancer Res 10:1971-5. 2004
    ..This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a matrix metalloproteinase inhibitor (MMPI), into adjuvant breast cancer therapy...
  45. ncbi request reprint Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer
    Antonio C Wolff
    J Clin Oncol 24:4949-51. 2006
  46. ncbi request reprint NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
    Robert W Carlson
    Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 4:S1-26. 2006
    ..This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting...
  47. ncbi request reprint Current status of taxanes as adjuvant therapy for early-stage breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland 21231 1000, USA
    Int J Fertil Womens Med 50:227-9. 2005
    ..In this commentary, we review much of the current data that support the use of taxanes in early-stage breast cancer...
  48. ncbi request reprint Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies
    Alex Sparreboom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA Rotterdam, The Netherlands
    Clin Cancer Res 9:151-9. 2003
    ..O. Bradley et al., Clin. Cancer Res., 7: 3229-3238, 2001). Here, we examined the role of protein binding as a determinant of the pharmacokinetic behavior of DHA-paclitaxel...
  49. ncbi request reprint American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Clin Oncol 23:7703-20. 2005
    ..To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer...
  50. ncbi request reprint Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers
    Joseph A Sparano
    Department of Oncology, Albert Einstein Cancer Center Montefiore Medical Center, Bronx, New York 10461, USA
    Drug Saf 25:301-11. 2002
    ..Clinical trials are currently evaluating the role of these markers in predicting both early and late, clinical and subclinical damage associated with anthracyclines and trastuzumab...
  51. ncbi request reprint Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Antonio C Wolff
    J Clin Oncol 24:2392-4; author reply 2394-5. 2006
  52. ncbi request reprint HER2 testing in breast cancer: NCCN Task Force report and recommendations
    Robert W Carlson
    Stanford Hospital and Clinics
    J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006
    ..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed...
  53. ncbi request reprint American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting
    James L Khatcheressian
    Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA
    J Clin Oncol 24:5091-7. 2006
    ..To update the 1999 American Society of Clinical Oncology (ASCO) guideline on breast cancer follow-up and management in the adjuvant setting...
  54. ncbi request reprint Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623
    Halle C F Moore
    Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 25:1677-82. 2007
    ....
  55. ncbi request reprint Invasive breast cancer
    Robert W Carlson
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:246-312. 2007
  56. ncbi request reprint American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 23:619-29. 2005
    ..To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors...
  57. ncbi request reprint Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
    Alex Sparreboom
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:4707-13. 2007
    ..Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese...
  58. ncbi request reprint American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  59. doi request reprint Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1810-6. 2008
    ..This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC)...
  60. ncbi request reprint 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline
    Thomas J Smith
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, Alexandria, VA 22314, USA
    J Clin Oncol 24:3187-205. 2006
    ..Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness...
  61. ncbi request reprint Breast cancer
    Robert W Carlson
    Stanford Hospital and Clinics, USA
    J Natl Compr Canc Netw 3:238-89. 2005
  62. ncbi request reprint Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer
    Sing Huang Tan
    Department of Hematology Oncology, National University Hospital, Singapore
    Clin Breast Cancer 7:455-64. 2007
    ....
  63. ncbi request reprint Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so
    Antonio C Wolff
    J Natl Cancer Inst 94:1041-3. 2002
  64. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
    ..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...